A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined with Pembrolizumab in Subjects with Selected Hyaluronan-High Solid Tumors
This study is being done to test the good and bad effects of PEGPH20 in combination with Pembrolizumab in men and women with hyaluronan-high non-small cell lung cancer or gastric adenocarcinoma.
Non-small cell lung cancer (NSCLC)
1. Men and women 18 years or older
2. Recurrent or metastatic solid tumors
3. Adequate organ function
4. Other criteria apply
18 - 89
Healthy Volunteers Needed
Duration of Participation
Participants will receive the study drug as long as their cancer does not get worse and they do not develop side effects that they cannot tolerate. After the last dose of the study drug, participants will be contacted by phone every 12 weeks until the end of the study, which is planned to be in two years.
Knight Clinical Trials Information Line